- Kalvista Pharmaceuticals Inc's (NASDAQ: KALV) oral plasma kallikrein inhibitor, KVD900, has reduced the use of rescue medication in patients suffering swelling attacks associated with hereditary angioedema (HAE), a disorder that results in recurrent episodes of severe swelling that most commonly affects the arms, legs, face, intestinal tract, and airway and is usually not itchy.
- The phase 2 clinical trial enrolled 53 adult HAE patients who had experienced three attacks in the 90 days before recruitment. All patients received a single, open-label 600-mg dose of KVD900 in the first stage of the study before being randomized to get the drug or placebo in the second crossover stage. The second stage tracked patients until they had two attacks to compare KVD900 to placebo.
- Fifteen percent of attacks treated with KVD900 required rescue medication in the 12 hours after onset, versus 30% of attacks in the placebo arm. The difference was statistically significant, causing the trial to hit its primary endpoint. The trial also linked KVD900 to reduced use of rescue medication at 24 hours.
- The median time to symptom relief in patients on KVD900 was 1.6 hours, comparing favorably to the nine hours for placebo. The time to symptom relief with KVD900 is in line with an injectable alternative, Ruconest, which typically takes 1.5 hours to ease an attack's effects.
- KalVista is now planning to hold an end-of-phase 2 meeting with the FDA before moving into phase 3.
- Price Action: KALV stock rallied 167% at $41.8 on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.